Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Lowered to $18.00 at HC Wainwright

Enanta Pharmaceuticals (NASDAQ:ENTA) had its price objective decreased by HC Wainwright from $27.00 to $18.00 in a research note released on Tuesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ FY2029 earnings at ($6.62) EPS.

Several other analysts have also commented on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $21.00 price target (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th. Robert W. Baird lowered their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $17.25.

Enanta Pharmaceuticals Stock Performance

NASDAQ:ENTA opened at $6.00 on Tuesday. The firm has a market cap of $127.16 million, a price-to-earnings ratio of -1.09 and a beta of 0.49. Enanta Pharmaceuticals has a one year low of $5.70 and a one year high of $17.80. The firm’s fifty day moving average is $9.40 and its two-hundred day moving average is $11.57.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The company had revenue of $14.60 million for the quarter, compared to analyst estimates of $17.99 million. During the same quarter in the prior year, the company posted ($1.33) earnings per share. The business’s revenue was down 22.8% on a year-over-year basis. As a group, equities research analysts predict that Enanta Pharmaceuticals will post -4.73 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Jay R. Luly sold 5,142 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the sale, the chief executive officer now owns 801,638 shares of the company’s stock, valued at approximately $6,461,202.28. This represents a 0.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 13.64% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ENTA. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Enanta Pharmaceuticals in the third quarter worth approximately $122,000. American Century Companies Inc. grew its holdings in Enanta Pharmaceuticals by 35.4% during the 2nd quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock valued at $362,000 after purchasing an additional 7,287 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in Enanta Pharmaceuticals by 65.8% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock worth $588,000 after buying an additional 18,003 shares during the period. Erste Asset Management GmbH purchased a new stake in Enanta Pharmaceuticals during the 3rd quarter worth $1,243,000. Finally, Point72 Asset Management L.P. acquired a new position in Enanta Pharmaceuticals in the 3rd quarter worth $903,000. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.